Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Deferred Tax Liability: 2023-2025

Historic Non-Current Deferred Tax Liability for Coherus Oncology (CHRS) over the last 2 years, with Sep 2025 value amounting to $1.1 million.

  • Coherus Oncology's Non-Current Deferred Tax Liability changed negligibly% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.1 million for FY2024, which is negligibly% changed negligibly from last year.
  • Per Coherus Oncology's latest filing, its Non-Current Deferred Tax Liability stood at $1.1 million for Q3 2025, which was down 0.00% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q3 2023 and a low of $1.1 million during Q3 2023.
  • Its 3-year average for Non-Current Deferred Tax Liability is $1.1 million, with a median of $1.1 million in 2025.